TRIBNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
TRINITY BIOTECH PLC
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 30, 2026
$8.19+0.16 (+1.99%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
TRINITY BIOTECH PLC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Laboratory Member | $31.68M | $39.37M | $42.29M | $46.04M | $62.88M | $84.28M | $68.13M | $71.62M | $73.37M | $74.17M | 72.3% | -19.5% |
| Point-of-Care [Member] | $8.10M | $17.43M | $9.09M | $9.21M | $10.34M | $9.22M | $11.39M | $14.84M | $16.77M | $16.91M | 18.5% | -53.5% |
| Clinical laboratory services [Member] | $4.01M | $4.75M | $5.45M | $7.27M | $7.93M | $8.49M | $10.92M | $10.58M | $9.00M | $8.54M | 9.1% | -15.7% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $51.98M | $61.61M | $66.85M | $76.62M | $116.31M | $136.99M | $103.61M | $104.53M | $108.24M | $103.21M | 118.7% | -15.6% |
| Americas [Member] | $24.62M | $29.92M | $32.28M | $35.56M | $52.78M | $70.41M | $52.18M | $57.56M | $59.54M | $61.61M | 56.2% | -17.7% |
| Asia Or Africa Member | $15.38M | $24.78M | $18.91M | $20.40M | $21.40M | $22.57M | $27.69M | $29.47M | $27.13M | $25.50M | 35.1% | -37.9% |
| Ireland | $15.00M | $20.47M | $12.72M | $12.84M | $16.42M | $25.39M | $28.02M | $34.07M | $36.64M | $41.07M | 34.3% | -26.7% |
| Europe (including Ireland) [Member] | $3.78M | $6.86M | $5.64M | $6.56M | $6.97M | $9.01M | – | – | – | – | 8.6% | -45.0% |
| Eliminations [Member] | -$23.19M | -$20.52M | -$22.74M | -$26.94M | -$51.58M | -$60.40M | -$41.19M | -$41.56M | -$45.73M | -$45.02M | -53.0% | +13.0% |
| XX | – | – | – | – | – | – | – | – | – | $352.00K | – | – |
| Europe (including Ireland) [Member] | – | – | – | – | $9.66M | $9.01M | $10.57M | $10.01M | $12.47M | $12.50M | – | – |
| Other Countries [Member] | – | – | – | – | $0 | $0 | $0 | – | – | $352.00K | – | – |
From the segment and revenue-disaggregation notes of Trinity Biotech's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.